Transcutaneous Tibial Nerve Stimulation Device Beneficial in Overactive Bladder
By Elana Gotkine HealthDay Reporter
TUESDAY, April 2, 2024 -- For patients with overactive bladder (OAB) symptoms, a wearable, smartphone-controlled, rechargeable transcutaneous tibial nerve stimulation (TTNS) device is efficacious and safe, according to a study published online March 11 in BJU International.
Limin Liao, M.D., Ph.D., from the China Rehabilitation Science Institute in Beijing, and colleagues conducted a prospective, randomized clinical trial involving eligible patients with OAB symptoms who were randomly assigned to a TTNS or sham group.
The researchers found that the mean change of voiding frequency/24 hours at four weeks was −3.5 and −0.6 in the stimulation and sham groups, respectively, in the full analysis set. The results were similar in the per-protocol set (−3.5 versus −0.4, respectively). Micturition volume/void significantly improved at four weeks in both the full analysis set and per-protocol set. The improvement in patient perception of bladder condition was almost significant in the full analysis set and was significant in the per-protocol set. The American Urological Association Symptom Index Quality of Life Score improved significantly in both groups in the full analysis and per-protocol sets; no significant differences were seen in urgency score/void, nocturia episodes/day, or overactive bladder symptom score. There were no reports of device-related serious adverse events.
"TTNS using the novel, wearable, smartphone-controlled, rechargeable, and ambulatory TTNS device is effective and safe for treating OAB," the authors write. "This approach could be a new potential home-based treatment modality."
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
![](/img/logo/vendor/healthday-logo.png)
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.